作者:Danny C. Lenstra、Peter E. Lenting、Jasmin Mecinović
DOI:10.1039/c8gc02136h
日期:——
A highly efficient and sustainable catalytic Staudingerreduction for the conversion of organic azides to amines in excellent yields has been developed. The reaction displays excellent functional group tolerance to functionalities that are otherwise prone to reduction, such as sulfones, esters, amides, ketones, nitriles, alkenes, and benzyl ethers. The green nature of the reaction is exemplified by
Influence of the Linking Bridge on the Photoreactivity of Benzophenone–Thymine Conjugates
作者:Alejandro Blasco-Brusola、Ignacio Vayá、Miguel A. Miranda
DOI:10.1021/acs.joc.0c02088
日期:2020.11.6
photosensitize DNA damage, where one of the most relevant BP/DNA interactions occurs with thymine (Thy). In view of the complex photoreactivity previously observed for dyads containing BP covalently linked to thymidine, the aim of this work is to investigate whether appropriate changes in the nature of the spacer could modulate the intramolecular BP/Thy photoreactivity, resulting in an enhanced selectivity. Accordingly
[EN] IMAGING AGENTS FOR NEURAL FLUX<br/>[FR] AGENTS D'IMAGERIE POUR FLUX NEURONAL
申请人:GEN HOSPITAL CORP
公开号:WO2016011394A1
公开(公告)日:2016-01-21
Provided herein are radiolabeled compounds useful for non-invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for positron emission tomography. The present application also provides unlabeled compounds useful in methods of treating diseases of the central nervous system or disease of the peripheral nervous system. Methods for preparing radiolabeled compounds, preparing unlabeled compounds, and diagnostic methods using labeled or unlabeled compounds are also provided.
Provided herein are radiolabeled compounds useful for non-invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for positron emission tomography. The present application also provides unlabeled compounds useful in methods of treating diseases of the central nervous system or disease of the peripheral nervous system. Methods for preparing radiolabeled compounds, preparing unlabeled compounds, and diagnostic methods using labeled or unlabeled compounds are also provided.